NOTICES

Week of May 18, 2015

- Findings of Research Misconduct
  (NOT-OD-15-100) National Institutes of Health
- Notice of Change to RFA-AI-15-005 "Molecular Mechanisms of Combination Adjuvants (MMCA) (U01)"
  (NOT-AI-15-035)
  National Institute of Allergy and Infectious Diseases
- Notice of National Cancer Institute (NCI) Participation in PA-14-154 "Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R43/R44)"
  (NOT-CA-15-017)
  National Cancer Institute
- Notice of National Cancer Institute (NCI) Participation in PA-14-157 "Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R41/R42)"
  (NOT-CA-15-018)
  National Cancer Institute
- Notice of Applicant Information Webinar for the NIBIB Program on Pediatric Research using Integrated Sensor Monitoring Systems (PRISMS): U01, U54, U24
  (NOT-EB-15-007)
  National Institute of Biomedical Imaging and Bioengineering
- Notice of Participation of NIMHD in PAR-13-055 "Dissemination and Implementation Research in Health (R01)"
  (NOT-MD-15-007)
  National Institute on Minority Health and Health Disparities
- Notice of Participation of NIMHD in PA-14-131 "Improving Delivery of HIV Prevention and Treatment through Implementation Science and Translational Research (R01)"
  (NOT-MD-15-008)
  National Institute on Minority Health and Health Disparities
- Notice of Intent to Publish a Funding Opportunity for a Clinical Trials Network for Emergency Care Research: Clinical Coordinating Center (U24)
  (NOT-NS-15-022)
  National Institute of Neurological Disorders and Stroke
  National Center for Advancing Translational Sciences
  National Heart, Lung, and Blood Institute
- Findings of Research Misconduct
  (NOT-OD-15-092) National Institutes of Health

REQUESTS FOR APPLICATIONS

- **TITLE:** Provocative Questions in Cancer With an Underlying HIV Infection (R21)
  (RFA-CA-15-013)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed "Provocative Questions" (PQs). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
  Application Receipt Date(s): 5pm on August 18, 2015

- **TITLE:** Development of Measures of Fatigability in Older Adults (R21)
  (RFA-AG-16-013)
  **SPONSOR:** National Institute on Aging, National Cancer Institute
  **Synopsis:** This FOA invites applications to develop and evaluate measures of fatigability. This FOA is not intended to support the addition of one more instrument to the extensive assortment of existing fatigue measures. Rather, this FOA is intended to substantially advance the science of disability measurement through development of a qualitatively different construct -- fatigability -- by addressing the inherent problem of self-pacing that confounds most measures of fatigue.
  Application Receipt Date(s): October 1, 2015.
• **TITLE:** Provocative Questions (PQ) Initiative; Cancer with an Underlying HIV Infection (R01)
  (RFA-CA-15-012)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed "Provocative Questions" (PQs). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
  Application Receipt Date(s): August 18, 2015.

**PROGRAM ANNOUNCEMENTS**

• **TITLE:** NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21)
  (PAR-13-146)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** The National Cancer Institute (NCI) Exploratory/Developmental Grant (R21) funding opportunity supports the development of new research activities in all areas of cancer research. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (biomedical, behavioral, or clinical).
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Revision Applications to U01 Awards on Detection of Pathogen-Induced Cancer (DPIC) (U01)
  (PAR-13-173)
  **SPONSOR:** National Cancer Institute
  **Synopsis:** This Funding Opportunity Announcement (FOA) invites cooperative agreement research (U01) revision applications (formerly called "competing revisions") from investigators with active NIH U01 research project awards. These revision applications are expected to focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 Cooperative Agreement.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Role of the Microflora in the Etiology of Gastro-Intestinal Cancer (R01)
  (PAR-14-242)
  **SPONSOR:** National Cancer Institute, National Institute on Alcohol Abuse and Alcoholism
  **Synopsis:** This Funding Opportunity Announcement (FOA) encourages innovative multidisciplinary research projects that will advance our mechanistic understanding of microflora influences on Gastro-Intestinal (GI) carcinogenesis. Recent advances in our knowledge of GI microflora composition and function have generated a flood of new information, technologies, and capabilities that may for the first time allow mechanistic investigations of very complex, networked host/microbiome interactions on a systems wide scale. This FOA encourages investigators to ingrate this new information into hypothesis-driven studies that can define and validate molecular mechanisms that determine microbe-induced carcinogenic outcomes. Applicants may integrate information from existing large data sets, including metagenomic data sets, or may also propose to generate appropriate new data sets, including but not limited to analysis of host and microbial genomes, proteomes, metabolomes, post-translational modifications, secreted signals, and protein-protein interaction data. An additional goal of this program is to encourage collaborative efforts between scientists currently engaged in GI cancer research with those in scientific disciplines that may not otherwise apply their expertise to study cancer etiology and prevention. A value added from stimulating integrated, multidisciplinary experimental approaches may include the discovery of emergent properties of the GI ecosystem that could not be elucidated using either descriptive bioinformatics or molecular studies alone.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

• **TITLE:** Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50)
  (PAR-13-318)
This Funding Opportunity Announcement (FOA) invites revision applications from currently funded NIH P01 program projects. Revision applications are expected to focus on combined imaging and biomarker approaches to improve screening, early cancer detection and diagnosis by integrating multi-modality imaging strategies and multiplexed biomarker methodologies. Depending on the context and focus of the parent P01 award, studies proposed in the revision application must correspond to a new research project expanding the scope of the parent Program Project while maintaining relevance to the overall focus of the parent grant.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** Revision Applications to P01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P01) (PA-13-317)

**SPONSOR:** National Cancer Institute

**Synopsis:** This Funding Opportunity Announcement (FOA) invites revision applications (formerly called "competing revisions") from currently funded NIH P01 program projects. Revision applications are expected to focus on combined imaging and biomarker approaches to improve screening, early cancer detection and diagnosis by integrating multi-modality imaging strategies and multiplexed biomarker methodologies. Depending on the context and focus of the parent P01 award, studies proposed in the revision application must correspond to a new research project expanding the scope of the parent Program Project while maintaining relevance to the overall focus of the parent grant.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** Research on Malignancies in the Context of HIV/AIDS (R01) (PA-13-377)

**SPONSOR:** National Cancer Institute, National Institute of Dental and Craniofacial Research

**Synopsis:** This funding opportunity announcement (FOA) encourages Research Project Grant (R01) applications from institutions/organizations that propose to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying Human Immunodeficiency (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS). The NCI and NIDCR encourage research in areas such as the study of the etiologic factors, cofactors, immunopathogenesis, diagnosis, and consequences of both non-AIDS defining and AIDS-defining malignancies in diverse populations. This FOA encourages research efforts that will (i) provide information on the clinical outcomes of such cancers in the HIV-infected population and (ii) identify specific contributions resulting from HIV infection and its potential interaction with other pathogens for the development and pathogenesis of these cancers. Ultimately, such efforts could inform screening approaches and therapies targeted to the HIV-infected population.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44) (PA-13-140)

**SPONSOR:** National Institute of Mental Health, National Cancer Institute, National Heart, Lung, and Blood, National Human Genome Research Institute, National Institute on Aging, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Center for Advancing Translational Sciences

**Synopsis:** This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) research grant applications to develop next-generation tools that distinguish heterogeneous states among cells and have commercial potential. Applications should define the current state of technology as a benchmark against which the new tool(s) will be measured. Applications should also propose proof-of-concept testing of the tool(s) in a complex biological tissue or living organism. The new tools should provide substantially increased sensitivity, selectivity, spatiotemporal resolution, scalability or non-destructive analysis of multiple global or functional measures of single cells. These novel technologies will aid in obtaining a fine-grained, integrative and dynamic view of heterogeneous cellular states/classes and will provide innovative platforms to transform research into the cellular basis of diseases.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

**TITLE:** Research Supplements to Promote Diversity in Health-Related Research (Admin Supp) (PA-12-149)

**SPONSOR:** National Institute for Occupational Safety and Health, National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Human Genome Research Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National
Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Drug Abuse, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, National Institute on Minority Health and Health Disparities, National Library of Medicine, Fogarty International Center, National Center for Complementary and Integrative Health, National Center for Advancing Translational Sciences, Office of Research Infrastructure Programs, Office of Dietary Supplements, Office of Strategic Coordination, Centers for Disease Control and Prevention

Synopsis: The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) hereby notify Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds are available for administrative supplements to improve the diversity of the research workforce by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be underrepresented in health-related research. Administrative supplements must support work within the scope of the original project.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Admin Supp) (PA-15-249)
  **SPONSOR:** National Cancer Institute, National Library of Medicine, National Eye Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Biomedical Imaging and Bioengineering, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Environmental Health Sciences, National Institute of General Medical Sciences, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Nursing Research, Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  **Synopsis:** The National Library of Medicine, in conjunction with NIH Institutes and Centers (ICs) named above, announces an Administrative Supplement opportunity available to eligible NIH awardees with active R01 grants and, in some cases, with the other active awards with the activity codes listed above. (see IC-specific details in the Activity Code section above). These administrative supplements provide funds to active awards of participating Institutes and Centers in order to enhance the storage, organization, management and use of electronic research data through the involvement of informationists, also known as in-context information specialists. The purposes of this administrative supplement program are (1) to enhance collaborative, multi-disciplinary basic and clinical research by integrating an information specialist into the research team in order to improve the capture, storage, organization, management, integration, presentation and dissemination of biomedical research data; and (2) to assess and document the value and impact of the informationist’s participation.
  Application Receipt/Submission Date(s): July 17, 2015.

- **TITLE:** Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R21/R33) (PAR-14-230)
  **SPONSOR:** National Institutes of Health, National Institute on Drug Abuse, National Institute of Mental Health, National Cancer Institute, National Institute on Alcohol Abuse and Alcoholism
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to provide support for grant applications to generate and conduct preliminary tests of targeted smoking cessation treatments for individuals with schizophrenia. Smokers with schizophrenia who have co-occurring alcohol and/or substance abuse disorders are also a population of interest. This FOA encourages Phased Innovation (R21/R33) applications that focus on early-stage, treatment generation and pilot clinical trials that are consistent with an experimental therapeutic approach. This approach requires the identification of a theory-derived target based on putative mechanisms of nicotine addiction in individuals with schizophrenia, and clear hypotheses about how an intervention directed at changing the target can lead to clinical benefits. Studies of novel interventions include, but are not limited to behavioral, pharmacological, physiological, learning- and device-based treatment approaches and targets thereof. This FOA provides support for up to two years (R21 phase) for protocol development and target identification and engagement studies, followed by up to 3 years of support (R33 phase) for exploratory/pilot studies to further evaluate target engagement and its prospective association with clinical benefits, and to evaluate the feasibility of conducting a larger trial.
  Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Exploratory Studies of Smoking Cessation Interventions for People with Schizophrenia (R33) (PAR-14-231)
  **SPONSOR:** National Institutes of Health, National Institute on Drug Abuse, National Institute of Mental Health, National Cancer Institute, National Institute on Alcohol Abuse and Alcoholism
  **Synopsis:** The purpose of this Funding Opportunity Announcement (FOA) is to provide support for grant applications of two major types. Type I will conduct exploratory testing of novel, targeted treatments for smoking cessation for individuals with schizophrenia. Type II will conduct exploratory testing of targeted implementation strategies of existing efficacious treatments at the service-delivery system level. Smokers with schizophrenia who have co-occurring alcohol and/or substance abuse disorders are also a population of interest. Under this FOA, trials should be designed so that
results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of interventions or implementation strategies. Studies of novel interventions include, but are not limited to behavioral, pharmacological, biologics-based, cognitive, device-based, interpersonal, physiological, or combined approaches. The R33 funding mechanism provides support for up to 3 years, for either application type. Ultimately, this R33 funding mechanism intends to speed the translation of emerging basic science findings of mechanisms and processes underlying treatments or implementation strategies into novel intervention approaches that can be efficiently tested for their promise to promote smoking cessation in individuals who have schizophrenia (Type I) or promote the adoption of experimentally-supported smoking cessation interventions within organizations that provide services to smokers with schizophrenia (Type II).

Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Administrative Supplements for Research on Dietary Supplements (Admin Supp)  
  **(PA-15-258)**  
  **SPONSOR:** Office of Dietary Supplements, John E. Fogarty International Center, National Center for Complementary and Integrative Health, National Cancer Institute, National Eye Institute, National Heart, Lung, and Blood Institute, National Institute on Aging, National Institute on Alcohol Abuse and Alcoholism, National Institute of Allergy and Infectious Diseases, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Environmental Health Sciences  
  **Synopsis:** This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention. Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease.

Application Receipt/Submission Date(s): Multiple dates, see announcement.

- **TITLE:** Discovery of the Genetic Basis of Structural Birth Defects and of Childhood Cancers: Gabriella Miller Kids First Pediatric Research Program (X01)  
  **(PAR-15-259)**  
  **SPONSOR:** NIH Roadmap Initiatives, National Heart, Lung, and Blood Institute, The Common Fund/Office of Strategic Coordination  
  Application Receipt/Submission Date(s): July 27, 2015

**OTHER FUNDING OPPORTUNITIES**  
(Sponsors in bold are NIH Peer Reviewed Organizations)

- **TITLE:** Cancer Prevention Fellowship Program (CPFP)  
  [https://cfp.f_cancer.gov/](https://cfp.f_cancer.gov/)  
  **SPONSOR:** United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute  
  **Synopsis:** The NCI Cancer Prevention Fellowship Program provides postdoctoral training opportunities in cancer prevention and control. Under the shared guidance of an individual NCI preceptor and the CPFP scientific staff, fellows will develop original research projects in cancer prevention and control. Collaboration with investigators throughout the NCI is encouraged. Preceptors who serve to guide and enrich each fellow's experience are selected from skilled investigators across all NCI divisions, participating FDA centers, or local academic institutions.

Application Receipt/Submission Date(s): August 25, 2015.

- **TITLE:** Travel Exchanges  
  **SPONSOR:** British Association for Cancer Research

- **TITLE:** Murray Jackson Clinical Training Fellowship (Medical)  
  [http://www.genesisoncology.org.nz/apply-for-a-grant](http://www.genesisoncology.org.nz/apply-for-a-grant)  
  **SPONSOR:** Genesis Oncology Trust

- **TITLE:** Neurofibromatosis Research Program (NFRP): Clinical Trial Award; Exploration - Hypothesis Development Award; Investigator-Initiated Research Award; New Investigator Award  
  **SPONSOR:** Department of Defense
Synopsis: Applications to the Fiscal Year 2015 (FY15) Neurofibromatosis Research Program (NFRP) are being solicited by the U.S. Army Medical Research Acquisitions Activity (USAMRAA). The FY15 NFRP strongly encourages research applications that specifically address the critical needs of the NF community in one or more of the following Areas of Emphasis:

- Health services research for NF
- Heterogeneity of neurofibromas and other NF-related tumors
- Manifestations of NF post-adolescence:
- Mechanisms of pain
- Novel disease and treatment response markers for NF using genomics, epigenetics, systems biology, metabolomics, or other similar approaches
- Target identification and drug discovery for the treatment of NF
- Environmental, nutritional, and other modifiers of NF

If the proposed research project does not address one of the FY15 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

- TITLE: Tuberous Sclerosis Complex Research Program: Exploration - Hypothesis Development Award; Idea Development Award; Pilot Clinical Trial Award
  SPONSOR: Department of Defense
  Synopsis: The mission of the FY15 TSCRP is to encourage innovative research aimed at understanding the pathogenesis and preventing and treating the manifestations of TSC. Within this context, the FY15 TSCRP encourages applications to address one or more of the following Focus Areas:
  - Mechanisms Underlying Clinical Manifestations: Epilepsy, Neurocognition and behavior, Tumor development and progression, Cell and animal models, Genetics and disease modifiers
  - Novel Therapeutic Strategies: Dose, timing, and duration of mTOR inhibitors and other therapeutics, New targets and combination therapies, Preclinical and clinical studies, Biomarkers, Preventative therapies

If the proposed research project does not address one of the FY15 Focus Areas, justification that the proposed research project addresses an important problem related to TSC research and/or patient care should be provided.

Application Receipt/Submission Date(s): May 6, 2015.

- TITLE: John Gavin Postdoctoral Fellowship
  SPONSOR: Genesis Oncology Trust

- TITLE: Education and Outreach Grants
  SPONSOR: Breast Cancer Alliance

- TITLE: Young Investigator Grants
  SPONSOR: Breast Cancer Alliance

- TITLE: Edward Mallinckrodt, Jr. Foundation Grant
  SPONSOR: Edward Mallinckrodt, Jr. Foundation

- TITLE: BD Biosciences Research Grants: Cancer Grants
  SPONSOR: BD Biosciences

- TITLE: Career Catalyst Research Grants (CCR)
  SPONSOR: Susan G. Komen for the Cure

- TITLE: Brian D. Novis Senior and Junior Research Award
  SPONSOR: International Myeloma Foundation